Literature DB >> 29551736

Predictors of Response to Terlipressin in Hepatorenal Syndrome.

Ayse L Mindikoglu1, Stephen C Pappas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29551736      PMCID： PMC6008198          DOI： 10.1016/j.cgh.2018.03.011

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  6 in total

1.  Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; Nagireddy Putluri; Sridevi Devaraj; David Sheikh-Hamad; John M Vierling; John A Goss; Abbas Rana; Gagan K Sood; Prasun K Jalal; Lesley A Inker; Robert P Mohney; Hocine Tighiouart; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; William R Hutson; Charles D Howell; Jean-Pierre Raufman; Laurence S Magder; Cristian Coarfa
Journal:  Transl Res       Date:  2017-12-12       Impact factor: 7.012

2.  Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

Authors:  Thomas D Boyer; Arun J Sanyal; Guadalupe Garcia-Tsao; Andres Blei; Daniel Carl; Alice S Bexon; Peter Teuber
Journal:  J Hepatol       Date:  2010-12-15       Impact factor: 25.083

Review 3.  New Developments in Hepatorenal Syndrome.

Authors:  Ayse L Mindikoglu; Stephen C Pappas
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-07       Impact factor: 11.382

4.  Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome.

Authors:  Salvatore Piano; Hartmut H Schmidt; Xavier Ariza; Alex Amoros; Antonietta Romano; Anna Hüsing-Kabar; Elsa Solà; Alexander Gerbes; Mauro Bernardi; Carlo Alessandria; Bernhard Scheiner; Marta Tonon; Miriam Maschmeier; Cristina Solè; Jonel Trebicka; Thierry Gustot; Frederik Nevens; Vicente Arroyo; Pere Gines; Paolo Angeli
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-31       Impact factor: 11.382

5.  Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.

Authors:  André Nazar; Gustavo Henrique Pereira; Mónica Guevara; Marta Martín-Llahi; Marie-Noëlle Pepin; Marcella Marinelli; Elsa Solá; María Eugenia Baccaro; Carlos Terra; Vicente Arroyo; Pere Ginès
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

6.  Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.

Authors:  A J Sanyal; T D Boyer; R T Frederick; F Wong; L Rossaro; V Araya; H E Vargas; K R Reddy; S C Pappas; P Teuber; S Escalante; K Jamil
Journal:  Aliment Pharmacol Ther       Date:  2017-03-29       Impact factor: 8.171
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.